EROZİV ORAL LİKEN PLANUS’TA ENJEKTE EDİLEBİLEN TROMBOSİTTEN ZENGİN FİBRİN: ÇİFT KÖR, BÖLÜNMÜŞ AĞIZ, RANDOMİZE KONTROLLÜ PİLOT ÇALIŞMA

Abstract

Amaç: Bu çalışmanın amacı, enjekte edilebilen trombositten zengin fibrin'nin  (i-PRF) eroziv liken planus (EOLP) lezyonları üzerindeki klinik etkisini değerlendirmek ve kortikosteroid tedavisi ile karşılaştırmaktır.

Gereç ve Yöntem: Yanak mukozasında çift taraflı EOLP bulunan 13 sistemik sağlıklı hastanın yanak mukozalarının bir tarafına i-PRF, diğer tarafına intralezyonel kortikosteroid enjeksiyonu yapılmıştır. Enjeksiyonlar 15 gün araya 4 seans tekrarlanmıştır. Sübjektif değerlendirme belirteci olarak görsel analog skala (VAS), objektif değerlendirme belirteci olarak Thongprasom skorları kullanılmıştır. Skorlamalar tedaviden önce, son enjeksiyon seansından hemen sonra, tedavi sonrası 1. ay ve tedavi sonrası 2. ay kontrol seanslarında yapılmıştır.

Bulgular: Gruplar arası karşılaştırmada, başlangıç ve kontrol seanslarında VAS-Ağrı , VAS-Memnuniyet ve Thongprasom skorlarında istatistiksel olarak anlamlı bir fark bulunamamıştır. Grup içi karşılaştırmalarda hem i-PRF uygulanan grupta (VAS-Ağrı 83,46 ± 16,25'ten 7,69 ± 9,92'ye düştü (p <0,001), VAS-Memnuniyet 26,54 ± 19,73'ten 87,31 ± 9,71'e yükseldi (p <0,001), Thongprasom skorları 4,85 ± 0,37'den 2,08 ± 1,04'e düştü (p = 0,001)), hem de kortikosteroid uygulanan grupta (VAS-Ağrı 83,46 ± 16,25'ten 10,77 ± 14,27'ye düştü (p <0,001), VAS-Memnuniyet 26,54 ± 19,72'den 84,23 ± 13,52'ye yükseldi (p <0,001), Thongprasom skorları 4,54 ± 0,52'den 2,00 ± 1,22’e düştü (p = 0,001))  VAS-Ağrı ve Thongprasom skorlarının ortalama değerlerinde istatistiksel olarak anlamlı bir düşüş görülürken, VAS-Memnuniyet skorlarının ortalamasında  istatistiksel olarak anlamlı bir artış gözlenmiştir.
Sonuç: Bu pilot çalışma, i-PRF enjeksiyonunun EOLP lezyonların tedavisinde altın standart kabul edilen kortikosteroid enjeksiyonuna benzer derecede etkili olabileceğini göstermiştir. 

Keywords

• Kortikosteroid
• Liken Planus
• Mukoza
• Trombositten Zengin Fibrin

INJECTABLE PLATELET RICH FIBRIN IN EROSIVE ORAL LICHEN PLANUS: A DOUBLE-BLIND, SPLIT- MOUTH, RANDOMIZED CONTROLLED PILOT STUDY

Abstract

Objective: The purpose of this study was to evaluate the clinical effect of injectable platelet-rich fibrin (i-PRF) at erosive lichen planus (EOLP) lesions and compare with corticosteroid therapy.

Material and Method: In 13 systemically healthy patients with bilateral EOLP in the buccal mucosa, i-PRF was injected on one side of the buccal mucosa and intralesional corticosteroid injection on the other side. The injections were repeated 4 sessions with 15 days interval. Visual analog scale (VAS) was used as subjective evaluation marker and Thongprasom scale were used as objective evaluation marker. Scores were performed before the treatment, immediately after the last injection session, at 1^st month post-treatment and at 2^nd months post-treatment control sessions.

Results: In the comparison between the groups, no statistically significant difference was found in the VAS-Pain, VAS-Satisfaction and Thongprasom scores at the baseline and control sessions. Intragroup comparisons were showed a statistically significant decrease in mean values of both VAS-Pain and Thongprasom scores, and a statistically significant increase in VAS-Satisfaction scores in both i-PRF  group (VAS-Pain decreased from 83,46 ± 16,25 to 7,69 ± 9,92 (p <0,001), Thongprasom scale decreased from 4,85 ± 0,37 to 2,08 ± 1,04 (p = 0,001)) and VAS-Satisfaction increased from 26,54 ± 19,73 to 87,31 ± 9 (p <0,001), and corticosteroid  group (VAS-Pain decreased from 83,46 ± 16,25 to 10,77 ± 14,27 (p <0,001), Thongprasom scale decreased from 4,54 ± 0,52 to 2,00 ± 1,22 (p = 0,001) and VAS-Satisfaction increased from 26,54 ± 19,72 to 84,23 ± 13,52 (p <0,001)). There was a statistically significant decrease in the mean values of VAS-Pain and Thongprasom scores, while a statistically significant increase was observed in the mean VAS-Satisfaction scores.

Conclusion: This pilot study showed that i-PRF infection could be as effective as corticosteroid injection, the gold standard in the treatment of EOLP lesions. 

Keywords

• Corticosteroid
• Lichen Planus
• Mucosa
• Platelet Rich Fibrine

References

1. Axell T, Rundquist L. Oral lichen planus--a demographic study. Community Dent Oral Epidemiol. 1987;15(1):52-6.
2. Altman J, Perry HO. The variations and course of lichen planus. Arch Dermatol. 1961;84:179-91.
3. Carrozzo M, Gandolfo S. The management of oral lichen planus. Oral diseases. 1999;5(3):196-205.
4. Holmstrup P, Schiøtz AW, Westergaard J. Effect of dental plaque control on gingival lichen planus. Oral Surgery, Oral Medicine, Oral Pathology. 1990;69(5):585-90.
5. Sivolella S, Berengo M, Cernuschi S, Valente M. Diode laser treatment is effective for plaque-like lichen planus of the tongue: a case report. Lasers in medical science. 2012;27(2):521-4.
6. Neville JA, Hancox JG, Williford PM, Yosipovitch G. Treatment of severe cutaneous ulcerative lichen planus with low molecular weight heparin in a patient with hepatitis C. Cutis. 2007;79(1):37-40.
7. Sadaksharam J, Nayaki KP, Selvam NP. Treatment of oral lichen planus with methylene blue mediated photodynamic therapy--a clinical study. Photodermatol Photoimmunol Photomed. 2012;28(2):97-101.
8. Lavanya N, Jayanthi P, Rao UK, Ranganathan K. Oral lichen planus: An update on pathogenesis and treatment. Journal of Oral and Maxillofacial Pathology. 2011;15(2):127.

9. Chan ES, Thornhill M, Zakrzewska JJ. Interventions for treating oral lichen planus. Cochrane Database of Systematic Reviews. 1999(2).
10. Bayramgürler D, Aktürk AŞ. İntralezyonel Kortikosteroid Tedavisi. Turkish Journal of Dermatology. 2014;8(4).
11. Miron RJ, Choukroun J. Platelet Rich Fibrin in Regenerative Dentistry: Biological Background and Clinical Indications: John Wiley & Sons; 2017.
12. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453(7193):314-21.
13. Choukroun J, Ghanaati S. Reduction of relative centrifugation force within injectable platelet-rich-fibrin (PRF) concentrates advances patients’ own inflammatory cells, platelets and growth factors: the first introduction to the low speed centrifugation concept. European Journal of Trauma and Emergency Surgery. 2018;44(1):87-95.
14. Piñas L, Alkhraisat MH, Fernández RS, Anitua E. Biological Therapy of Refractory Ulcerative Oral Lichen Planus with Plasma Rich in Growth Factors. American Journal of Clinical Dermatology. 2017;18(3):429-33.
15. Thongprasom K, Luengvisut P, Wongwatanakij A, Boonjatturus C. Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2‐year follow‐up. Journal of oral pathology & medicine. 2003;32(6):315-22.
16. Trehan M, Taylor CR. Low-dose excimer 308-nm laser for the treatment of oral lichen planus. Archives of dermatology. 2004;140(4):415-20.
17. Clementini M, Discepoli N, Danesi C, de Sanctis M. Biologically guided flap stability: the role of flap thickness including periosteum retention on the performance of the coronally advanced flap–A double‐blind randomized clinical trial. Journal of clinical periodontology. 2018;45(10):1238-46.
18. Cairo F, Barbato L, Tonelli P, Batalocco G, Pagavino G, Nieri M. Xenogeneic collagen matrix versus connective tissue graft for buccal soft tissue augmentation at implant site. A randomized, controlled clinical trial. J Clin Periodontol. 2017;44(7):769-76.
19. Aghahosseini F, Arbabi-Kalati F, Fashtami LA, Fateh M, Djavid GE. Treatment of oral lichen planus with photodynamic therapy mediated methylene blue: a case report. Medicina Oral, Patología Oral y Cirugía Bucal (Internet). 2006;11(2):126-9.
20. Mostafa D, Moussa E, Alnouaem M. Evaluation of photodynamic therapy in treatment of oral erosive lichen planus in comparison with topically applied corticosteroids. Photodiagnosis and Photodynamic Therapy. 2017;19:56-66.
21. Xia J, Li C, Hong Y, Yang L, Huang Y, Cheng B. Short-term clinical evaluation of intralesional triamcinolone acetonide injection for ulcerative oral lichen planus. J Oral Pathol Med. 2006;35(6):327-31.
22. Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med. 1992;21(10):456-8.
23. Fricain JC, Sibaud V, Campana F, Lepreux S, Taieb A. Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus. Dermatology. 2005;210(3):229-32.
24. Byrd JA, Davis MD, Bruce AJ, Drage LA, Rogers RS. Response of oral lichen planus to topical tacrolimus in 37 patients. Archives of dermatology. 2004;140(12):1508-12.
25. Lozada-Nur F, Miranda C, Maliksi R. Double-blind clinical trial of 0.05% clobetasol propionate (corrected from proprionate) ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol. 1994;77(6):598-604.
26. Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med. 2002;13(4):350-65.
27. Setterfield JF, Black MM, Challacombe SJ. The management of oral lichen planus. Clin Exp Dermatol. 2000;25(3):176-82.
28. Thongprasom K, Mravak-Stipetic M, Luckprom P, Canjuga I, Biocina-Lukenda D, Vidovic-Juras D, et al. Oral lichen planus: a retrospective comparative study between Thai and Croatian patients. Acta Dermatovenerol Croat. 2009;17(1):2-8.
29. Thongprasom K, Youngnak-Piboonratanakit P, Pongsiriwet S, Laothumthut T, Kanjanabud P, Rutchakitprakarn L. A multicenter study of oral lichen planus in Thai patients. J Investig Clin Dent. 2010;1(1):29-36.
30. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46(2):207-14.
31. Abdallat SA, Maaita TJ. Epidemiological and clinical features of lichen planus in Jordanian patients. Pakistan journal of medical sciences. 2007;23(1):92.
32. Lozada-Nur F, Huang MZ, Zhou GA. Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol. 1991;71(3):283-7.
33. Lozada F, Silverman JS, Migliorati C. Adverse side effects associated with prednisone in the treatment of patients with oral inflammatory ulcerative diseases. Journal of the American Dental Association (1939). 1984;109(2):269-70.
34. McCreary CE, McCartan BE. Clinical management of oral lichen planus. Br J Oral Maxillofac Surg. 1999;37(5):338-43.
35. Silverman S, Jr., Gorsky M, Lozada-Nur F, Giannotti K. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 1991;72(6):665-70.
36. Silverman S, Jr., Gorsky M, Lozada-Nur F. A prospective follow-up study of 570 patients with oral lichen planus: persistence, remission, and malignant association. Oral Surg Oral Med Oral Pathol. 1985;60(1):30-4.
37. Silverman S, Jr., Lozada-Nur F, Migliorati C. Clinical efficacy of prednisone in the treatment of patients with oral inflammatory ulcerative diseases: a study of fifty-five patients. Oral Surg Oral Med Oral Pathol. 1985;59(4):360-3.
38. Lozada-Nur F, Luangjarmekorn L, Silverman S, Jr., Karam J. Assessment of plasma glucose in 99 patients with oral lichen planus. J Oral Med. 1985;40(2):60-1.
39. Zegarelli DJ. Topical and intralesional steroid therapy of oral lichen planus. N Y State Dent J. 1980;46(7):432, 4-6.
40. Zegarelli DJ. Multimodality steroid therapy of erosive and ulcerative oral lichen planus. J Oral Med. 1983;38(3):127-30.
41. Zegarelli DJ. Ulcerative and erosive lichen planus. Treated by modified topical steroid and injection steroid therapy. N Y State Dent J. 1987;53(3):23-4.
42. Roitberg‐Tambur A, Friedmann A, Korn S, Markitziu A, Pisanti S, Satirman C, et al. Serologic and molecular analysis of the HLA system in Israeli Jewish patients with oral erosive lichen planus. Tissue Antigens. 1994;43(4):219-23.
43. Wadia R. Lichen planus and oral health-related quality of life. British dental journal. 2019;227(1):37.
44. Wadia R. Role of plaque control in gingival oral lichen planus. British dental journal. 2019;227(1):37.
45. Sahebjamee M, Bakhshi MAM. Efficacy of topical retinoic acid compared with topical triamcinolone acetonide in the treatment of oral lichen planus. Acta Medica Iranica. 2004:108-13.
46. Chainani-Wu N, Silverman S, Jr., Lozada-Nur F, Mayer P, Watson JJ. Oral lichen planus: patient profile, disease progression and treatment responses. J Am Dent Assoc. 2001;132(7):901-9.
47. Sobaniec S, Bernaczyk P, Pietruski J, Cholewa M, Skurska A, Dolińska E, et al. Clinical assessment of the efficacy of photodynamic therapy in the treatment of oral lichen planus. Lasers in medical science. 2013;28(1):311-6.
48. EL‐Komy MHM, Hassan AS, Raheem HMA, Doss SS, EL‐Kaliouby M, Saleh NA, et al. Platelet‐rich plasma for resistant oral erosions of pemphigus vulgaris: A pilot study. Wound Repair and Regeneration. 2015;23(6):953-5.
49. Miron RJ, Fujioka-Kobayashi M, Hernandez M, Kandalam U, Zhang Y, Ghanaati S, et al. Injectable platelet rich fibrin (i-PRF): opportunities in regenerative dentistry? Clin Oral Investig. 2017;21(8):2619-27.